antibiotics and tirzepatide (Mounjaro) In Sherman Oaks FDA approves tirzepatide, Eli Lilly's

Adverse reactions to drugs medicines guidance

Semaglutide has been associated with modest increases in heart rate in some patients, warranting cardiovascular monitoring in susceptible individuals

What the Clinical Evidence Shows While large-scale randomized controlled trials specifically measuring testosterone as a primary endpoint in tirzepatide users are still emerging, the available evidence is encouraging: The SURMOUNT trials demonstrated average weight losses of 15-22.5% of body weight, a degree of fat reduction strongly associated with testosterone recovery in men with obesity-related hypogonadism (Jastreboff et al., 2022, NEJM )

But why now

While pre-clinical data has been encouraging, clinical evidence remains limited